Recombinant EGFR (Zalutumumab Biosimilar) antibody
Quick Overview for Recombinant EGFR (Zalutumumab Biosimilar) antibody (ABIN7487875)
Target
Antibody Type
Reactivity
Host
Clonality
Conjugate
Application
Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Zalutumumab Biosimilar - Anti-EGFR mAb
-
Characteristics
- Antibody Type: IgG1-kappa
-
Purification
- Recombinant antibody expressed in mammalien cells and purified.
-
Isotype
- IgG1 kappa
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Buffer
- PBS pH 7.5
-
Storage
- -80 °C
-
Storage Comment
- store at -80°C
-
-
- EGFR (Zalutumumab Biosimilar)
-
Target Type
- Biosimilar
-
Background
-
HuMax-EGFr
Zalutumumab (proposed trade name HuMax-EGFR) is a high affinity, completely human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFR, also known as ErbB1/HER1). It is developed by Genmab and designed for the treatment of squamous cell carcinoma of the head and neck (SCCHN), a type of cancer. Zalutumumab is derived from transgenic mice immunized with A431-derived EGFR. -
CAS-No
- 667901-13-5
Target
-